Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women

HIV Treatment Bulletin - Vol. 8, No. 10, October 2007

There have been conflicting results from studies evaluating the effect of hormonal contraceptive use on the risk of HIV acquisition.

Recent data from a study conducted in Uganda and Zimbabwe found that women using hormonal contraception had an increased risk if they were herpes simplex virus type 2 (HSV-2) negative, but not if they were HSV-2 positive. This difference in risk was highly significant (p=0.003).

A paper in the August 20 2007 edition of AIDS authored by Jared Baeten and coworkers reported findings from a study to examine the effect of HSV-2 on the relationship between hormonal contraception and HIV-1 in a high-risk population. [1]

This group had previously found in a study of female Kenyan sex workers, both oral contraceptive pill and depot medroxyprogesterone acetate (DMPA) use were associated with increased risk of HIV aquisition. [2]. HSV-2 was not assessed in that analysis. The investigators re-examined the data to evaluate the effect of HSV-2 on the relationship between hormonal contraception and HIV.

Data were from a prospective cohort study of 1206 HIV-negative sex workers from Mombasa, Kenya who were followed monthly.At enrollment, 171 (14.2%) women used oral contraceptive pills and 244 (20.2%) DMPA. 234 (19.4%) women were HSV-2 negative and 972 (80.6%) were HSV-2 positive. 84 women who were HSV-negative at enrollment seroconverted during the study period.

The investigators found 233 women acquired HIV-1 (8.7/100 person-years). HSV-2 prevalence (81%) and incidence (25.4/100 person-years) were high. In multivariate analysis, including adjustment for HSV-2, HIV acquisition was associated with use of oral contraceptive pills [adjusted hazard ratio (HR), 1.46; 95% confidence interval (CI), 1.00–2.13] and DMPA (adjusted HR, 1.73; 95% CI, 1.28–2.34).

The effect of hormonal contraception on HIV acquisition was not significantly different between HSV-2 negative versus positive women. HSV-2 infection was associated with increased HIV risk (adjusted HR, 3.58; 95% CI, 1.64–7.82).

The investigators concluded: “In this group of high-risk African women, hormonal contraception and HSV-2 infection were both associated with increased risk for HIV-1 acquisition. HIV-1 risk associated with hormonal contraceptive use was not related to HSV-2 serostatus.”

References

1. Baeten JM, Benki S, Chohan V et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007, 21:1771–1777

2. Lavreys L, Baeten JM, Martin HL et al. Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS 2004; 18:695–697.

2007-10-10
IB070810-12

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.